DotBio
- Company typePrivate
- Founded2017
- HeadquartersSingapore, Singapore
- Headcount11–50
- GTM typeB2B
- OfferingServices
DotBio firmographics
Firmographics- Name
- DotBio
- Website
- https://dotbiopharma.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
DotBio industry classification
Industry- Product category
- Biopharmaceutical Therapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Bispecific & Multispecific Antibodies (HLAAAAAF)
- akta.pro secondary industry
- Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)
Keywords
Where DotBio is headquartered
LocationHeadquarters
- HQ city
- Singapore
- HQ country
- Singapore
- HQ region
- Asia
Offices1 record
Markets served
DotBio business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations
Revenue model
- Biopharmaceutical Development: Pre-revenue biopharmaceutical company developing multifunctional antibody therapeutics. Revenue model not yet established as company is in early research and development stage following recent pre-Series A funding.
DotBio product offering
Product offeringCore offering
DotBio develops multi-functional antibodies based on its proprietary DotBody technology as next-generation cancer therapies. The Singapore-based biopharmaceutical company engineers antibody candidates designed to engage multiple therapeutic targets simultaneously, addressing complex diseases through its preclinical antibody pipeline.
Product overview
DotBio is a Singapore-based biopharmaceutical company focused on developing multifunctional antibodies. The company raised $5.6 million in a pre-Series A funding round in 2023 to support its research and development efforts. No specific named products or modules were identified in the available sources.
Differentiator
Problem solved
Functional benefit
Products and services
- DotBody Multifunctional Antibody Pipeline
Companies that use DotBio
Customer profileIdeal customer profiles1 record
DotBio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
DotBio partnerships and signals
Strategic signalScale indicators2 records
Recent moves4 records
Expansion highlights4 records
DotBio competitors and assessment
Company assessmentBroad incumbents
- Genmab: Genmab is a leading antibody therapeutics company and the developer of the DuoBody bispecific antibody platform, making it a direct strategic reference point for DotBio's DotBody multifunctional antibody approach.
- Innovent Biologics: Innovent is a leading Chinese biopharmaceutical company with a portfolio that includes bispecific antibodies (e.g., PD-1-based bispecifics), representing an established Asia-based peer with overlap in multifunctional oncology biologics.
Direct peers
- Zymeworks: Zymeworks develops multifunctional and bispecific antibody therapeutics using its proprietary platforms (e.g., Azymetric), closely paralleling DotBio's DotBody-based multifunctional antibody strategy in oncology.
- AbCellera Biologics: AbCellera is an antibody discovery and engineering platform company building multispecific candidates, representing a comparable platform-based business model to DotBio's DotBody technology.
- Akeso, Inc. Akeso is an Asia-based biopharmaceutical company with a leading pipeline of bispecific and multispecific antibody oncology drugs, making it a strong geographic and modality peer for DotBio.
- Dragonfly Therapeutics: Dragonfly is developing multispecific antibody-based therapeutics (e.g., its TriNKET platform) for cancer and immune diseases, a close functional analogue to DotBio's multifunctional antibody focus.
Emerging players
- Adagene: Adagene is an Asia-headquartered (China/Singapore) clinical-stage biotech developing antibody-based therapeutics including bispecifics, an emerging regional peer with comparable modality and geography to DotBio.
- Cullinan Oncology: Cullinan Oncology is a clinical-stage oncology company developing bispecific antibodies and immune-engaging therapeutics, comparable as a smaller oncology-focused biologics developer.
- Atreca: Atreca develops antibody-based therapeutics using a proprietary immune repertoire platform, comparable to DotBio as a platform-driven antibody discovery company in oncology.
Others
- WuXi Biologics: WuXi Biologics is a leading Asia-based biologics contract development and manufacturing organization that supports bispecific/multispecific antibody developers like DotBio with discovery, manufacturing, and IND-enabling services.
Market position
Strengths3 records
Weaknesses3 records
Competitive moat2 records
Key risks4 records
Key highlights4 records
Customer concentration
DotBio financial estimates
Financial estimateRevenue estimate
Valuation estimate
DotBio leadership team
Management profileNumber of profiles
Profiles1 record
DotBio funding detail
Funding detailFunding overview
Funding rounds4 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
DotBio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about DotBio
What does DotBio do?
DotBio develops multi-functional antibodies based on its proprietary DotBody technology as next-generation cancer therapies. The Singapore-based biopharmaceutical company engineers antibody candidates designed to engage multiple therapeutic targets simultaneously, addressing complex diseases through its preclinical antibody pipeline.
Is DotBio a public or private company?
DotBio is a private company. It is classified as venture growth investor backed and is currently operating.
When was DotBio founded?
DotBio was founded in 2017. It employs 11 to 50 people.
Where is DotBio based?
DotBio is headquartered in Singapore, Singapore, in the Asia region.
How does DotBio make money?
One revenue line is on record: biopharmaceutical Development.
Who are DotBio's main competitors?
Broad incumbents on record are Genmab and Innovent Biologics. Direct peers are Zymeworks, AbCellera Biologics, Akeso, Inc. and Dragonfly Therapeutics. Emerging players are Adagene, Cullinan Oncology and Atreca. WuXi Biologics is listed as an others.
Does DotBio have an API?
No public API is recorded for DotBio.
What industry is DotBio in?
DotBio's product category is Biopharmaceutical Therapeutics. Its primary akta.pro industry code is HLAAAAAF, Bispecific & Multispecific Antibodies, with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 325414 and its SIC code is 2836.